Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
20.3M
Short interest
settlement 2026-09-30
3.1
Days to cover
+0.9 days vs prior
36.4%
Short share of volume
2026-10-09
108
Fails to deliver
settlement 2026-09-11
Tue 3 Nov
Next earnings
estimated date
-$184K
Insider flow, 90 days
0 buys, 4 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in RARE is 20,349,877 shares, up 3,205,523 shares over the last month. Over the last 48 readings it ranged from 3,164,918 shares (15 October 2024) to 20,349,877 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 6.5M shares a day that is 3.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rare" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 20,349,877 | +22.8% | 6,502,013 | 3.13 |
| 2026-09-15 | 16,571,956 | -3.3% | 7,461,648 | 2.22 |
| 2026-08-31 | 17,144,354 | +7.9% | 2,143,209 | 8.00 |
| 2026-08-14 | 15,887,767 | +6.2% | 2,042,547 | 7.78 |
| 2026-07-31 | 14,963,396 | +11.4% | 1,807,137 | 8.28 |
| 2026-07-15 | 13,435,087 | -17.2% | 1,937,159 | 6.94 |
| 2026-06-30 | 16,217,153 | +13.3% | 4,501,008 | 3.60 |
| 2026-06-15 | 14,312,759 | -2.7% | 1,617,040 | 8.85 |
| 2026-05-29 | 14,703,432 | +5.2% | 1,495,515 | 9.83 |
| 2026-05-15 | 13,976,318 | +2.3% | 1,699,704 | 8.22 |
| 2026-04-30 | 13,665,812 | +13.1% | 1,626,704 | 8.40 |
| 2026-04-15 | 12,088,495 | +5.9% | 1,705,231 | 7.09 |
| 2026-03-31 | 11,413,679 | +14.9% | 2,371,600 | 4.81 |
| 2026-03-13 | 9,932,072 | +3.5% | 2,079,795 | 4.78 |
| 2026-02-27 | 9,597,141 | -2.7% | 1,776,857 | 5.40 |
| 2026-02-13 | 9,861,470 | +8.4% | 2,518,345 | 3.92 |
| 2026-01-30 | 9,095,903 | +2.6% | 2,359,920 | 3.85 |
| 2026-01-15 | 8,861,656 | +10.5% | 3,256,998 | 2.72 |
| 2025-12-31 | 8,017,399 | -6.8% | 4,264,555 | 1.88 |
| 2025-12-15 | 8,600,577 | -3.0% | 1,518,656 | 5.66 |
| 2025-11-28 | 8,871,538 | +13.3% | 1,237,643 | 7.17 |
| 2025-11-14 | 7,828,953 | +9.6% | 1,468,323 | 5.33 |
| 2025-10-31 | 7,144,800 | -17.8% | 1,268,645 | 5.63 |
| 2025-10-15 | 8,692,947 | +13.6% | 1,410,509 | 6.16 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of RARE volume is 36.4%, down 8.8 points over the last five sessions. Over the last 30 readings it ranged from 26.8% (24 September 2026) to 59.3% (1 October 2026). The latest reading is 6.4 points below the 30-session average of 42.9%, on 1.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 384K | 1.1M | 36.4% | 1,717 |
| 2026-10-08 | 859K | 2.0M | 43.4% | 2,921 |
| 2026-10-07 | 566K | 1.8M | 31.5% | 679 |
| 2026-10-06 | 691K | 1.6M | 42.1% | 3,947 |
| 2026-10-05 | 694K | 2.0M | 34.6% | 259 |
| 2026-10-02 | 684K | 1.5M | 45.3% | 127 |
| 2026-10-01 | 754K | 1.3M | 59.3% | 9,102 |
| 2026-09-30 | 985K | 1.8M | 54.0% | 150 |
| 2026-09-29 | 996K | 2.4M | 41.6% | 502 |
| 2026-09-28 | 732K | 1.5M | 47.7% | 148 |
| 2026-09-25 | 859K | 2.3M | 37.9% | 636 |
| 2026-09-24 | 537K | 2.0M | 26.8% | 0 |
| 2026-09-23 | 1.2M | 2.4M | 51.2% | 7,262 |
| 2026-09-22 | 1.6M | 3.8M | 41.8% | 8,005 |
| 2026-09-21 | 914K | 2.7M | 34.5% | 2,805 |
| 2026-09-18 | 2.9M | 5.0M | 58.1% | 4,665 |
| 2026-09-17 | 2.2M | 5.2M | 43.0% | 8,501 |
| 2026-09-16 | 1.1M | 2.3M | 48.4% | 8,015 |
| 2026-09-15 | 930K | 2.3M | 40.9% | 10,639 |
| 2026-09-14 | 914K | 2.0M | 46.3% | 13,788 |
| 2026-09-11 | 517K | 1.2M | 44.0% | 5,265 |
| 2026-09-10 | 630K | 1.6M | 40.5% | 0 |
| 2026-09-09 | 710K | 1.7M | 42.3% | 0 |
| 2026-09-08 | 1.0M | 2.4M | 44.4% | 100 |
| 2026-09-04 | 2.3M | 5.6M | 40.5% | 372,110 |
| 2026-09-03 | 6.5M | 13.5M | 47.9% | 746,401 |
| 2026-09-02 | 401K | 773K | 51.8% | 0 |
| 2026-09-01 | 243K | 896K | 27.1% | 0 |
| 2026-08-31 | 258K | 596K | 43.3% | 12 |
| 2026-08-28 | 197K | 496K | 39.7% | 600 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 11 September 2026, the fails-to-deliver balance in RARE is 108 shares, down 159,089 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (7 April 2026) to 233,066 shares (3 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-11 | 108 | $14.40 | $2K |
| 2026-09-03 | 159,197 | $26.53 | $4.2M |
| 2026-08-28 | 111 | $26.26 | $3K |
| 2026-08-26 | 505 | $26.46 | $13K |
| 2026-08-24 | 1,756 | $25.83 | $45K |
| 2026-08-20 | 156 | $26.24 | $4K |
| 2026-07-30 | 290 | $25.00 | $7K |
| 2026-07-20 | 188 | $29.28 | $6K |
| 2026-07-17 | 10 | $30.22 | $302 |
| 2026-07-16 | 55 | $31.71 | $2K |
| 2026-06-18 | 1 | $26.91 | $27 |
| 2026-06-15 | 840 | $24.35 | $20K |
| 2026-06-08 | 11,279 | $21.91 | $247K |
| 2026-06-03 | 233,066 | $21.78 | $5.1M |
| 2026-06-02 | 131 | $22.85 | $3K |
| 2026-05-12 | 22 | $26.30 | $579 |
| 2026-05-08 | 2,198 | $26.13 | $57K |
| 2026-04-20 | 3,100 | $24.81 | $77K |
| 2026-04-15 | 100 | $24.57 | $2K |
| 2026-04-07 | 1 | $22.87 | $23 |
| 2026-03-23 | 9 | $19.87 | $179 |
| 2026-03-17 | 100 | $21.82 | $2K |
| 2026-03-11 | 300 | $22.84 | $7K |
| 2026-02-24 | 395 | $22.51 | $9K |
| 2026-02-23 | 1,300 | $22.72 | $30K |
| 2026-02-20 | 175 | $21.83 | $4K |
| 2026-02-18 | 351 | $20.18 | $7K |
| 2026-01-07 | 12,265 | $22.54 | $276K |
| 2026-01-05 | 8,065 | $23.60 | $190K |
| 2025-12-31 | 119,004 | $22.78 | $2.7M |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at RARE reported 4 open-market sells worth $184K in the last 90 days and no open-market buys. Latest filing: Huizenga Theodore Alan (SVP, Chief Accounting Officer) on 2026-09-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 1K | $13.57 | $17K | 68K |
| 2026-09-03 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 161 | $13.99 | $2K | 69K |
| 2026-08-03 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 2K | $24.92 | $47K | 93K |
| 2026-08-03 | Horn Howard | Chief Financial Officer | Sell | 5K | $24.92 | $117K | 96K |
| 2026-07-01 | Horn Howard | Chief Financial Officer | Sell | 5K | $33.13 | $156K | 101K |
| 2026-06-15 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 2K | $24.62 | $47K | 94K |
| 2026-06-15 | Sanders Corazon (Corsee) D. | Director | Sell | 2K | $25.05 | $50K | 21K |
| 2026-06-01 | Horn Howard | Chief Financial Officer | Sell | 5K | $23.77 | $111K | 106K |
| 2026-05-18 | SULIMAN SHEHNAAZ | Director | Sell | 6K | $25.12 | $144K | 28K |
| 2026-05-14 | WELCH DANIEL G | Director | Grant | 8K | $0.00 | $0 | 40K |
| 2026-05-14 | Sanders Corazon (Corsee) D. | Director | Grant | 8K | $0.00 | $0 | 23K |
| 2026-05-14 | SULIMAN SHEHNAAZ | Director | Grant | 8K | $0.00 | $0 | 34K |
| 2026-05-14 | Ray Amrit | Director | Grant | 8K | $0.00 | $0 | 31K |
| 2026-05-14 | NARACHI MICHAEL | Director | Grant | 8K | $0.00 | $0 | 40K |
| 2026-05-14 | Fust Matthew K | Director | Grant | 8K | $0.00 | $0 | 34K |
| 2026-05-14 | Dunsire Deborah | Director | Grant | 8K | $0.00 | $0 | 39K |
| 2026-05-05 | Crombez Eric | EVP and Chief Medical Officer | Sell | 344 | $24.96 | $9K | 111K |
| 2026-05-01 | Horn Howard | Chief Financial Officer | Sell | 5K | $24.90 | $117K | 110K |
| 2026-04-22 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Grant | 20K | $0.00 | $0 | 69K |
| 2026-04-16 | Pinion John Richard | See Remarks | Grant | 23K | $0.00 | $0 | 133K |
| 2026-04-16 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Grant | 29K | $0.00 | $0 | 96K |
| 2026-04-16 | KAKKIS EMIL D | President & CEO | Grant | 77K | $0.00 | $0 | 736K |
| 2026-04-16 | Huang Dennis Karl | See Remarks | Grant | 23K | $0.00 | $0 | 148K |
| 2026-04-16 | Horn Howard | Chief Financial Officer | Grant | 35K | $0.00 | $0 | 115K |
| 2026-04-16 | Harris Erik | EVP & Chief Commercial Officer | Grant | 29K | $0.00 | $0 | 118K |
| 2026-04-16 | Crombez Eric | EVP and Chief Medical Officer | Grant | 35K | $0.00 | $0 | 111K |
| 2026-04-01 | Horn Howard | Chief Financial Officer | Sell | 5K | $20.97 | $98K | 80K |
| 2026-03-10 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 4K | $22.67 | $80K | 67K |
| 2026-03-06 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 6K | $21.40 | $129K | 70K |
| 2026-03-03 | Horn Howard | Chief Financial Officer | Sell | 2K | $22.40 | $37K | 85K |
| 2026-03-02 | Pinion John Richard | See Remarks | Sell | 10K | $22.80 | $229K | 110K |
| 2026-03-02 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 8K | $22.80 | $185K | 76K |
| 2026-03-02 | KAKKIS EMIL D | President & CEO | Sell | 54K | $22.80 | $1.2M | 659K |
| 2026-03-02 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 2K | $22.80 | $37K | 49K |
| 2026-03-02 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Tax withholding | 148 | $23.39 | $3K | 50K |
| 2026-03-02 | Huang Dennis Karl | See Remarks | Tax withholding | 999 | $23.39 | $23K | 125K |
| 2026-03-02 | Horn Howard | Chief Financial Officer | Sell | 3K | $22.54 | $70K | 87K |
| 2026-03-02 | Horn Howard | Chief Financial Officer | Sell | 5K | $22.80 | $121K | 90K |
| 2026-03-02 | Harris Erik | EVP & Chief Commercial Officer | Sell | 11K | $22.80 | $240K | 90K |
| 2026-03-02 | Crombez Eric | EVP and Chief Medical Officer | Sell | 7K | $22.80 | $160K | 76K |
| 2026-03-01 | Pinion John Richard | See Remarks | Grant | 11K | $0.00 | $0 | 120K |
| 2026-03-01 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Grant | 11K | $0.00 | $0 | 84K |
| 2026-03-01 | KAKKIS EMIL D | President & CEO | Grant | 71K | $0.00 | $0 | 713K |
| 2026-03-01 | Huang Dennis Karl | See Remarks | Grant | 11K | $0.00 | $0 | 126K |
| 2026-03-01 | Horn Howard | Chief Financial Officer | Grant | 6K | $0.00 | $0 | 95K |
| 2026-03-01 | Harris Erik | EVP & Chief Commercial Officer | Grant | 12K | $0.00 | $0 | 99K |
| 2026-03-01 | Crombez Eric | EVP and Chief Medical Officer | Grant | 12K | $0.00 | $0 | 83K |
| 2026-02-02 | Horn Howard | Chief Financial Officer | Sell | 3K | $23.56 | $72K | 89K |
| 2026-01-02 | Horn Howard | Chief Financial Officer | Sell | 3K | $22.84 | $72K | 92K |
| 2025-12-29 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 85 | $34.38 | $3K | 50K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON16 Form 144 notices on file for RARE worth $1.5M at the prices reported; 2 in the last 90 days worth $134K. Latest: THEODORE HUIZENGA filed on 2026-09-15 to sell 1,283 shares ($17K) from 2026-09-15.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-15 | THEODORE HUIZENGAOfficer | 1K | $17K | 0.001% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | HOWARD HORNOfficer | 5K | $117K | 0.005% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | HOWARD HORNOfficer | 5K | $156K | 0.005% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-15 | CORAZON D. SANDERSDirector | 2K | $50K | 0.002% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-15 | KARAH PARSCHAUEROfficer | 4K | $93K | 0.004% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | HOWARD HORNOfficer | 5K | $111K | 0.005% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-18 | SHEHNAAZ SULIMANDirector | 6K | $144K | 0.006% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | HOWARD HORNOfficer | 5K | $117K | 0.005% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-01 | HOWARD HORNOfficer | 5K | $98K | 0.005% | 2026-04-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-10 | KARAH PARSCHAUEROfficer | 4K | $80K | 0.004% | 2026-03-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | KARAH PARSCHAUEROfficer | 6K | $129K | 0.006% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | HOWARD HORNOfficer | 2K | $37K | 0.002% | 2026-03-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | HOWARD HORNOfficer | 3K | $70K | 0.003% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | HOWARD HORNOfficer | 3K | $72K | 0.003% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-02 | HOWARD HORNOfficer | 3K | $72K | 0.003% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-10 | HOWARD HORNOfficer | 3K | $112K | 0.003% | 2025-12-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON8 holders report 5% or more of RARE in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 8.3% of the class (8,141,384 shares), filed 2026-07-30 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G | Roderick Wongparent holding company, individual | 7.8M | 7.9% | 2026-06-30 |
| 2026-08-14 | 13G | RTW Investments, LPinvestment adviser, partnership | 7.8M | 7.9% | 2026-06-30 |
| 2026-08-13 | 13G | AQR Capital Management Holdings, LLCparent holding company | 6.6M | 6.7% | 2026-06-30 |
| 2026-08-13 | 13G | AQR Capital Management, LLCinvestment adviser | 6.6M | 6.7% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 6.2M | 6.3% | 2026-06-30 |
| 2026-07-31 | 13G/Ano. 1 | Vanguard Portfolio Managementinvestment adviser | 6.9M | 7.0% | 2026-06-30 |
| 2026-07-31 | 13G | Vanguard Capital Managementinvestment adviser | 5.1M | 5.1% | 2026-06-30 |
| 2026-07-30 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 8.1M | 8.3% | 2026-06-30 |
| 2026-03-27 | 13G/Ano. 10 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-05 | 13G/Ano. 1 | FMR LLCparent holding company | 3.3M | 3.5% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 3.3M | 3.5% | 2025-12-31 |
13F holders
Tracked managers holding RARE at their latest 13F. JSON6 of the 30 tracked managers held RARE at their latest 13F, $439.1M in total at quarter-end prices. AQR Capital Management is the largest at $214.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 6.6M | $214.1M | 0.07% | +2.0M |
| Two Sigma Investments | 2026-06-30 | 3.6M | $120.9M | 0.09% | +1.4M |
| D. E. Shaw & Co. | 2026-06-30 | 1.7M | $57.8M | 0.03% | +469K |
| Millennium Management | 2026-06-30 | 761K | $25.4M | 0.01% | -1.0M |
| Renaissance Technologies | 2026-06-30 | 414K | $13.8M | 0.02% | -148K |
| Citadel Advisors | 2026-06-30 | 211K | $7.0M | 0.00% | -1.9M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Ultragenyx Pharmaceutical reported revenue of $214.0M, up 28.1% from the same quarter a year earlier, and net loss of $92.0M (-0.90 diluted EPS). In FY 2025 it generated -$466.0M of operating cash flow.
- Cash
- $125.0M
- Equity
- -$291.0M
- Total assets
- $1.26B
- Shares outstanding
- 98,588,873
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $214.0M | -$92.0M | -43.0% | -0.90 |
| Q1 FY 2026 | 2026-03-31 | $136.0M | -$185.0M | -136.0% | -1.84 |
| Q4 FY 2025derived | 2025-12-31 | $207.1M | -$128.6M | -62.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $159.9M | -$180.4M | -112.8% | -1.81 |
| Q2 FY 2025 | 2025-06-30 | $167.0M | -$115.0M | -68.9% | -1.17 |
| Q1 FY 2025 | 2025-03-31 | $139.0M | -$151.0M | -108.6% | -1.57 |
| Q4 FY 2024derived | 2024-12-31 | $164.6M | -$133.2M | -80.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $139.5M | -$133.5M | -95.7% | -1.40 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $673.0M | -$575.0M | -$466.0M | $6.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $560.0M | -$569.0M | -$414.0M | $7.0M | n/a | n/a |
| FY 2023 | 2023-12-31 | $434.0M | -$607.0M | -$475.0M | $44.0M | n/a | n/a |
| FY 2022 | 2022-12-31 | $363.3M | -$707.4M | -$380.5M | $116.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $351.4M | -$454.0M | -$338.7M | $73.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Ultragenyx Pharmaceutical in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Ultragenyx Pharmaceutical (RARE), SEC CIK 1515673, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-11.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1515673Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of RARE is sold short?
What is RARE's daily short volume?
Does RARE have fails to deliver?
Are RARE insiders buying or selling?
Have RARE insiders filed to sell?
Who owns 5% or more of RARE?
What did RARE report last quarter?
Which tracked 13F managers own RARE?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.